NCT02400749 - Apremilast in Palmo-Plantar Psoriasis | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions

Palmo-plantar Psoriasis

Interventions

DRUG

Apremilast

"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."

DRUG

Placebo

Placebo tablets will be provided to sites in blister cards.

Trial Locations (11)

Unknown

Innovaderm Investigational Site, Arlington Heights

Innovaderm Investigational Site, Calgary

Innovaderm Investigational Site, St. John's

Innovaderm Investigational Site, Barrie

Innovaderm Investigational Site, Markham

Innovaderm Investigational Site, North Bay

Innovaderm Investigational Site, Peterborough

Innovaderm Investigational Site, Drummondville

Innovaderm Investigational Site, Montreal

Innovaderm Investigational Site, Saint-Jérôme

Innovaderm Investigational Site, Québec